2022 was an important year for triglyceride-related research, with extensive clinical and preclinical data presented at international congresses and published in leading journals. When we asked Editorial Advisory Board members for their highlights, they agreed that the PROMINENT trial of triglyceride (TG) lowering to reduce cardiovascular (CV) risk, published in November 2022, was a major milestone.
Genetic testing for pancreatitis risk
Genetic testing may help identify patients with hypertriglyceridemia who are at greatest risk of developing pancreatitis and may benefit from novel triglyceride-lowering therapies, US researchers have concluded.
PROMINENT trial misses primary endpoint
Newly published results of the PROMINENT trial have shown that the SPPARα modulator, pemafibrate, affects a range of plasma lipid levels in patients with type 2 diabetes and mild-to-moderate hypertriglyceridemia (fasting median 271 mg/dL), but does not reduce cardiac events.
New APOC3 loss-of-function data support apoCIII as a treatment target for CV disease prevention
Newly published data on the postprandial kinetics of apoB48 and B100 in chylomicrons, VLDL1, VLDL2, IDL and LDL, in people heterozygous for a loss-of-function (LOF) mutation in the APOC3 gene, indicate the potential benefits of apoCIII lowering for cardiovascular disease (CVD) prevention.
REDUCE-IT biomarker data raise more questions than answers
REDUCE-IT trial participants allocated to icosapent ethyl had minimal changes in biomarkers associated with atherosclerotic disease, a new sub-study has shown. In contrast, there were increases in biomarker levels in those allocated to the mineral oil used as placebo in the trial. At baseline, median levels of each biomarker were similar in REDUCE-IT participants randomly […]
Cholesterol crystals: the next target for intervention in atherosclerotic cardiovascular disease?
Professor John Chapman (Pitié-Salpetrière University Hospital, INSERM, Paris France) discusses the crucial role of cholesterol crystals in atherothrombosis and the evidence suggesting that ethyl eicosapentaenoic acid may modify crystal formation and deposition, with implications for therapeutic intervention in atherosclerotic cardiovascular disease (ASCVD).